Compare BLKB & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLKB | OGN |
|---|---|---|
| Founded | 1981 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2004 | 2020 |
| Metric | BLKB | OGN |
|---|---|---|
| Price | $30.44 | $13.56 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 5 |
| Target Price | ★ $50.00 | $11.40 |
| AVG Volume (30 Days) | 892.6K | ★ 2.3M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ 142.32 | N/A |
| EPS | ★ 0.67 | 0.55 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | $6.26 | $0.45 |
| Revenue Next Year | $4.25 | $1.67 |
| P/E Ratio | $44.93 | ★ $24.60 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.58 | $5.69 |
| 52 Week High | $74.86 | $13.60 |
| Indicator | BLKB | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.83 | 73.60 |
| Support Level | $28.88 | $10.05 |
| Resistance Level | $32.93 | N/A |
| Average True Range (ATR) | 1.48 | 0.06 |
| MACD | 0.61 | -0.05 |
| Stochastic Oscillator | 86.73 | 78.57 |
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.